These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Angiotensin receptor blockers and secondary stroke prevention: the MOSES study. Dowlatshahi D; Hill MD Expert Rev Cardiovasc Ther; 2009 May; 7(5):459-64. PubMed ID: 19419253 [TBL] [Abstract][Full Text] [Related]
24. [Hypertension therapy for type 2 diabetics]. Bönner G MMW Fortschr Med; 2007 Jun; 149(23):45, 47-8. PubMed ID: 18062579 [No Abstract] [Full Text] [Related]
25. The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study. Fossum E; Moan A; Kjeldsen SE; Devereux RB; Julius S; Snapinn SM; Edelman JM; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Dahlöf B; J Am Coll Cardiol; 2005 Sep; 46(5):770-5. PubMed ID: 16139123 [TBL] [Abstract][Full Text] [Related]
26. ACE inhibitors and ARBs: antihypertensive medications in CKD. Szromba C Nephrol Nurs J; 2005; 32(3):332-3. PubMed ID: 16035474 [No Abstract] [Full Text] [Related]
27. [Study on cognition and prognosis in the elderly]. Kohara K Nihon Rinsho; 2006 Aug; 64 Suppl 6():425-30. PubMed ID: 16981574 [No Abstract] [Full Text] [Related]
28. Antihypertensive treatment and stroke prevention: are angiotensin receptor blockers superior to other antihypertensive agents? Armario P; de la Sierra A Ther Adv Cardiovasc Dis; 2009 Jun; 3(3):197-204. PubMed ID: 19443514 [TBL] [Abstract][Full Text] [Related]
29. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Onuigbo MA Arch Intern Med; 2009 Oct; 169(19):1810; author reply 1810-1. PubMed ID: 19858442 [No Abstract] [Full Text] [Related]
31. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998 [TBL] [Abstract][Full Text] [Related]
32. [Optimizing antihypertensive therapy. In 5 years 35,000 strokes are preventable]. MMW Fortschr Med; 2004 Jul; 146(27-28):52. PubMed ID: 15526671 [No Abstract] [Full Text] [Related]
33. Living up to expectations? AT1-receptor blockers in clinical trials. Cheung R Int J Clin Pract Suppl; 2000 Aug; (111):25-8. PubMed ID: 15977404 [No Abstract] [Full Text] [Related]
34. Blood pressure reduction is not the only determinant of outcome. Sever PS; Poulter NR; Elliott WJ; Jonsson MC; Black HR; Sever PS; Poulter NR; Elliott WJ; Jonsson MC; Black HR Circulation; 2006 Jun; 113(23):2754-72; discussion 2773-4. PubMed ID: 16769926 [No Abstract] [Full Text] [Related]
35. Comparative evaluation of the antihypertensive activities of losartan and HM70186 during liver dysfunction. Lee S Arch Pharm Res; 2009 Jul; 32(7):965-6. PubMed ID: 19641875 [No Abstract] [Full Text] [Related]
36. Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors. Aksnes TA; Reims HM; Guptha S; Moan A; Os I; Kjeldsen SE J Hum Hypertens; 2006 Nov; 20(11):860-6. PubMed ID: 16988754 [TBL] [Abstract][Full Text] [Related]
37. [Scientific evidence--applied in routine general practice. Successful decrease in pressure and risk]. MMW Fortschr Med; 2006 May; 148(18):42-3. PubMed ID: 16736689 [No Abstract] [Full Text] [Related]